Our aim is to identify biomarkers (genes, gene products and pathways) of importance for diagnosis and that have prognostic relevance in serous effusions, uterine sarcomas, vulvar cancer and melanoma. Furthermore, we aim to identify potential therapeutic targets and develop a screening platform facilitating clinical treatment decision.
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
Soluble AXL is ubiquitously present in malignant serous effusions
Gynecol Oncol, 152 (2), 408-415